Compare
VivoSim Labs, Inc. vs Zivo Bioscience, Inc. vs Entera Bio Ltd. vs Pluri Inc.
| Latest fiscal year | VivoSim Labs, Inc. VIVS | Zivo Bioscience, Inc. ZIVOLast annual report: year ended 2024-12-31 | Entera Bio Ltd. ENTX | Pluri Inc. PLUR |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2024-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $131.0K | $157.2K | $42.0K | $1.02M |
| Revenue growth (YoY) | -9.0% | +468.6% | -76.8% | -24.0% |
| Gross margin | n/a | 31.1% | 0.0% | 44.6% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.84M | -$13.38M | -$11.44M | -$23.82M |
| EPS (Diluted) | -$5.35 | -$4.23 | $0.25 | -$2.44 |
| Operating cash flow | -$10.83M | -$4.31M | -$7.37M | -$19.59M |
| Free cash flow | -$10.83M | n/a | -$7.48M | -$20.22M |
| Cash & equivalents | $5.02M | n/a | $7.11M | $3.53M |
| Total assets | $7.39M | $1.64M | $15.99M | $24.88M |
| Total liabilities | $8.48M | $2.16M | $2.89M | n/a |
| Shareholders' equity | -$1.10M | -$514.9K | $13.10M | -$23.04M |
| Return on year-end equity | n/a | n/a | -87.3% | n/a |
| Shares outstanding | 2.89M | 3.62M | 46.18M | 10.82M |
Revenue, most recent five fiscal years
| Fiscal year | VivoSim Labs, Inc. | Zivo Bioscience, Inc. | Entera Bio Ltd. | Pluri Inc. |
|---|---|---|---|---|
| Latest | $131.0K Ended 2026-03-31 | $157.2K Ended 2024-12-31 | $42.0K Ended 2025-12-31 | $1.02M Ended 2026-06-30 |
| 1 year earlier | $144.0K Ended 2025-03-31 | $27.6K Ended 2023-12-31 | $181.0K Ended 2024-12-31 | $1.34M Ended 2025-06-30 |
| 2 years earlier | $109.0K Ended 2024-03-31 | $0 Ended 2022-12-31 | $0 Ended 2023-12-31 | $326.0K Ended 2024-06-30 |
| 3 years earlier | $370.0K Ended 2023-03-31 | $0 Ended 2021-12-31 | $134.0K Ended 2022-12-31 | $287.0K Ended 2023-06-30 |
| 4 years earlier | $1.50M Ended 2022-03-31 | $20.0K Ended 2020-12-31 | $571.0K Ended 2021-12-31 | $234.0K Ended 2022-06-30 |